BRAF and metastatic colorectal cancer: For instance, melanoma patients with the BRAF V600E mutation may benefit from targeted therapy drugs aimed at the BRAF protein, such as vemurafenib (brand name: Zelboraf) and dabrafenib (brand name: Tafinlar)10; in colorectal cancer patients, the regimen of encorafenib (brand name: Braftovi) combined with cetuximab (brand name: Erbitux) has been approved in the United States for use in patients with metastatic colorectal cancer (mCRC) with the BRAF V600E mutation who have previously undergone treatment and whose disease has progressed.11